Nicholas Kadysh, CEO at PharmAla Biotech
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Nicholas Kadysh, CEO at PharmAla Biotech
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this episode, we welcome Nicholas Kadysh, CEO of PharmAla Biotech, the company pioneering GMP MDMA production and named the top-performing stock on the Canadian capital markets in 2023 by The Market Herald.
As Chair of Psychedelics Canada, Nicholas has been instrumental in advancing legal and ethical standards, building strong relationships with government, and shaping a regulatory landscape where healthcare innovation can thrive. His leadership has also been recognized by The Peak, which honored him in 2023 for emerging leadership in healthcare.
Tune in for an insightful conversation on the future of psychedelic medicine, biotech innovation, and the policies driving change in healthcare.
Pas encore de commentaire